Vanguard Capital Management
SLDB icon

Vanguard Capital Management’s Solid Biosciences SLDB Stock Holding History

Vanguard Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.1M Buy
4,009,922
+1,335,298
+50% +$10.1M ﹤0.01% 2070
2026
Q1 		$19.3M Buy
+2,674,624
New +$17.2M ﹤0.01% 2364

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management's SLDB Position: Q2 2026 in Review

Vanguard Capital Management increased its Solid Biosciences (SLDB) stake by 50% in Q2 2026, buying an estimated $10.1M and bringing the position to 4,009,922 shares worth $40.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2070.

Vanguard Capital Management first reported a position in SLDB in Q1 2026 and has held it in 2 quarters since. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Vanguard Capital Management held 4,009,922 shares of Solid Biosciences worth $40.1M as of Q2 2026.
  • Vanguard Capital Management bought 1,335,298 Solid Biosciences shares in Q2 2026, an estimated $10.1M.
  • Solid Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2070 holding.
  • Vanguard Capital Management first reported a position in Solid Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.